Program Name:
Novartis Healthcare Philippines, Inc.
Partners:
- World Health Organization (WHO)
- Department of Health (DOH)
- Local Government Units (LGUs)
- Leprosy advocacy groups
- Novartis Foundation for Sustainable Development
Year Started:
2000
Target Condition:
Leprosy
Who Can Benefit:
Patients with leprosy
Program Description
Since its inception in 2000, Novartis Healthcare Philippines, Inc., in partnership with the World Health Organization (WHO), has been at the forefront of global leprosy control. The program has provided nearly 100% of the world’s supply of multidrug therapy (MDT) for leprosy at no cost, equivalent to a donation valued at approximately $77 million. This initiative has contributed to curing around 5 million leprosy patients globally.
In the Philippines, Novartis has supplied over 47,000 MDT courses, accounting for more than 60% of WHO’s total MDT supply to the country since 1995.
MDT: A Breakthrough Treatment
Recommended by WHO since 1981, MDT has transformed the treatment of leprosy. The therapy involves three essential drugs:
- Dapsone
- Rifampicin
- Clofazimine
This combination therapy:
- Cures patients.
- Interrupts leprosy transmission.
- Prevents disabilities.
Patients, even those with the most severe forms of the disease, show significant clinical improvement within weeks of starting MDT. Two of these critical drugs, rifampicin and clofazimine, were developed in Novartis research laboratories.
In October 2010, Novartis and WHO announced an extension of their collaboration to provide free MDT medicines until 2015. During this five-year commitment, the program aimed to treat an estimated 1.1 million leprosy patients worldwide. Novartis also committed an additional $2.5 million to support WHO’s logistical and operational costs.
Where to Go
Patients can seek assistance and treatment at their Municipal or City Health Center.
For Questions and Assistance
For more information about the program, patients are encouraged to contact their Municipal or City Health Center for guidance and support.
The Leprosy Control Program is a shining example of public-private partnerships making a tangible difference in global health. By providing free and effective treatment, the program has significantly reduced the burden of leprosy worldwide and continues to improve the lives of countless individuals. If you or someone you know is affected by leprosy, do not hesitate to seek help at your local health center.
